EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Michael Weller*, Martin van den Bent, Kirsten Hopkins, Jörg C. Tonn, Roger Stupp, Andrea Falini, Elizabeth Cohen-Jonathan-Moyal, Didier Frappaz, Roger Henriksson, Carmen Balana, Olivier Chinot, Zvi Ram, Guido Reifenberger, Riccardo Soffietti, Wolfgang Wick

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

588 Scopus citations


This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.

Original languageEnglish (US)
Pages (from-to)e395-e403
JournalThe Lancet Oncology
Issue number9
StatePublished - Aug 2014

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma'. Together they form a unique fingerprint.

Cite this